Ocugen, Inc.
OCGN · XNASCIK 1372299fmd_0H8S7Y74TM4GZVF57F8M4ZQBKFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 4 | 4 |
| Provision for credit losses | – | – | – | 0 | 0 | 1 | 0 | – | – | – |
| Research and development | 22 | 16 | 10 | 8 | 6 | 35 | 56 | 40 | 32 | 40 |
| Total operating expenses | 30 | 25 | 16 | 14 | 21 | 58 | 92 | 72 | 59 | 67 |
| Operating income | (30) | (25) | (16) | (14) | (21) | (58) | (89) | (66) | (55) | (63) |
| Interest expense | 0 | – | 4 | 2 | 1 | 0 | – | – | 1 | 5 |
| Interest and investment income | – | – | 0 | 0 | 0 | – | – | – | 1 | 1 |
| Other non-operating income (expense) | 14 | (1) | (2) | (6) | (1) | (0) | 2 | 2 | 1 | (5) |
| Income before taxes | (16) | (26) | (9) | (20) | (22) | (58) | (87) | (63) | (54) | (68) |
| Income tax expense | – | – | – | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (20) | (22) | (58) | (87) | (63) | (54) | (68) |
| Net income | (16) | (26) | (18) | (20) | (22) | (58) | (87) | (63) | (54) | (68) |
| Net income to common shareholders | (14) | (22) | (18) | (20) | (34) | (58) | (87) | (63) | – | – |